1
|
Mackie I, Mancini I, Muia J, Kremer Hovinga J, Nair S, Machin S, Baker R. International Council for Standardization in Haematology (ICSH) recommendations for laboratory measurement of ADAMTS13. Int J Lab Hematol 2020; 42:685-696. [DOI: 10.1111/ijlh.13295] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/07/2020] [Revised: 06/15/2020] [Accepted: 07/02/2020] [Indexed: 12/17/2022]
Affiliation(s)
- Ian Mackie
- Research Haematology University College London London UK
| | - Ilaria Mancini
- Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Università degli Studi di Milano Department of Pathophysiology and Transplantation and Fondazione Luigi Villa Milan Italy
| | - Joshua Muia
- Department of Medicine Washington University School of Medicine St Louis MO USA
| | - Johanna Kremer Hovinga
- Department of Hematology and Central Hematology Laboratory Inselspital Bern University Hospital Bern Switzerland
| | - Sukesh Nair
- Transfusion Medicine and Immunohematology Christian Medical College Vellore India
| | - Sam Machin
- Research Haematology University College London London UK
| | - Ross Baker
- Western Australia Centre for Thrombosis and Haemostasis Perth Blood Institute Murdoch University Perth WA Australia
| |
Collapse
|
2
|
Guo C, Tsigkou A, Lee MH. ADAMTS13 and 15 are not regulated by the full length and N-terminal domain forms of TIMP-1, -2, -3 and -4. Biomed Rep 2015; 4:73-78. [PMID: 26870338 DOI: 10.3892/br.2015.535] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/29/2015] [Accepted: 07/15/2015] [Indexed: 11/06/2022] Open
Abstract
A disintegrin and metalloproteinase with thombospondin motifs (ADAMTS) 13 and 15 are secreted zinc proteinases involved in the turnover of von Willebrand factor and cancer suppression. In the present study, ADAMTS13 and 15 were subjected to inhibition studies with the full-length and N-terminal domain forms of tissue inhibitor of metalloproteinases (TIMPs)-1 to -4. TIMPs have no ability to inhibit the ADAMTS proteinases in the full-length or N-terminal domain form. While ADAMTS13 is also not sensitive to the hydroxamate inhibitors, batimastat and ilomastat, ADAMTS15 can be effectively inhibited by batimastat (Kiapp 299 nM). In conclusion, the present results indicate that TIMPs are not the regulators of these two ADAMTS proteinases.
Collapse
Affiliation(s)
- Cenqi Guo
- Department of Biological Sciences, Xian Jiaotong-Liverpool University, Suzhou, Jiangsu 215123, P.R. China
| | - Anastasia Tsigkou
- Department of Biological Sciences, Xian Jiaotong-Liverpool University, Suzhou, Jiangsu 215123, P.R. China
| | - Meng Huee Lee
- Department of Biological Sciences, Xian Jiaotong-Liverpool University, Suzhou, Jiangsu 215123, P.R. China
| |
Collapse
|
3
|
Ekaney ML, Bockmeyer CL, Sossdorf M, Reuken PA, Conradi F, Schuerholz T, Blaess MF, Friedman SL, Lösche W, Bauer M, Claus RA. Preserved Expression of mRNA Coding von Willebrand Factor-Cleaving Protease ADAMTS13 by Selenite and Activated Protein C. Mol Med 2015; 21:355-63. [PMID: 25860876 DOI: 10.2119/molmed.2014.00202] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/09/2014] [Accepted: 04/03/2015] [Indexed: 12/16/2022] Open
Abstract
In sepsis, the severity-dependent decrease of von Willebrand factor (VWF)-inactivating protease, a disintegrin and metalloproteinase with thrombospondin motifs 13 (ADAMTS13), results in platelet aggregation and consumption, leading to sepsis-associated thrombotic microangiopathy (TMA) and organ failure. Previous reports assessing its functional deficiency have pinpointed involvement of autoantibodies or mutations to propagate thrombotic thrombocytopenic purpura (TTP). However, mechanisms of acquired ADAMTS13 deficiency during host response remain unclear. To enhance understanding of ADAMTS13 deficiency in sepsis, we evaluated changes in expression of mRNA coding ADAMTS13 during septic conditions using primary cellular sources of the protease. We hypothesized that proinflammatory cytokines and constituents of serum from septic patients affect the transcriptional level of ADAMTS13 in vitro, and previously recommended therapeutic agents as adjunctive therapy for sepsis interact therewith. Cultured hepatic stellate cells (HSCs), endothelial cells (HMEC) and human precision-cut liver slices as an ex vivo model were stimulated with sepsis prototypic cytokines, bacterial endotoxin and pooled serum obtained from septic patients. Stimulation resulted in a significant decrease in ADAMTS13 mRNA between 10% and 80% of basal transcriptional rates. Costimulation of selenite or recombinant activated protein C (APC) with serum prevented ADAMTS13 decrease in HSCs and increased ADAMTS13 transcripts in HMEC. In archived clinical samples, the activity of ADAMTS13 in septic patients treated with APC (n = 5) increased with an accompanying decrease in VWF propeptide as surrogate for improved endothelial function. In conclusion, proinflammatory conditions of sepsis repress mRNA coding ADAMTS13 and the ameliorating effect by selenite and APC may support the concept for identification of beneficial mechanisms triggered by these drugs at a molecular level.
Collapse
Affiliation(s)
- Michael L Ekaney
- Center for Sepsis Control and Care, Jena University Hospital, Jena, Germany.,Clinic for Anaesthesiology and Intensive Care Medicine, Jena University Hospital, Jena, Germany
| | | | - Maik Sossdorf
- Center for Sepsis Control and Care, Jena University Hospital, Jena, Germany.,Clinic for Anaesthesiology and Intensive Care Medicine, Jena University Hospital, Jena, Germany
| | - Philipp A Reuken
- Center for Sepsis Control and Care, Jena University Hospital, Jena, Germany.,Clinic for Anaesthesiology and Intensive Care Medicine, Jena University Hospital, Jena, Germany
| | - Florian Conradi
- Clinic for Anaesthesiology and Intensive Care Medicine, Jena University Hospital, Jena, Germany
| | - Tobias Schuerholz
- Department for Interdisciplinary Intensive Care, University Hospital Aachen, Aachen, Germany
| | - Markus F Blaess
- Center for Sepsis Control and Care, Jena University Hospital, Jena, Germany.,Clinic for Anaesthesiology and Intensive Care Medicine, Jena University Hospital, Jena, Germany
| | - Scott L Friedman
- Mount Sinai School of Medicine, New York, New York, United States of America
| | - Wolfgang Lösche
- Center for Sepsis Control and Care, Jena University Hospital, Jena, Germany.,Clinic for Anaesthesiology and Intensive Care Medicine, Jena University Hospital, Jena, Germany
| | - Michael Bauer
- Center for Sepsis Control and Care, Jena University Hospital, Jena, Germany.,Clinic for Anaesthesiology and Intensive Care Medicine, Jena University Hospital, Jena, Germany
| | - Ralf A Claus
- Center for Sepsis Control and Care, Jena University Hospital, Jena, Germany.,Clinic for Anaesthesiology and Intensive Care Medicine, Jena University Hospital, Jena, Germany
| |
Collapse
|